Published in

Oxford University Press, Modern Rheumatology Case Reports, 2024

DOI: 10.1093/mrcr/rxae001

Links

Tools

Export citation

Search in Google Scholar

Streptococcal toxic shock syndrome due to Streptococcus dysgalactiae subsp. equisimilis from retroperitoneal panniculitis during the treatment with anti-IL-6 receptor antibody: A case report

Journal article published in 2024 by Sho Fujimoto ORCID, Yoshihiro Eriguchi ORCID, Rinto Nakamura, Sota Kamikawa, Akiko Yonekawa, Noriko Miyake, Nobuyuki Ono, Hiroaki Niiro ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

ABSTRACT A 53-year-old man with adult-onset Still’s disease developed severe streptococcal toxic shock syndrome (STSS) due to Streptococcus dysgalactiae subsp. equisimilis (SDSE), following retroperitoneal panniculitis. He was receiving tocilizumab (TCZ), an interleukin-6 receptor inhibitor. The modifying effect of TCZ on the immune response and the pathophysiology of SDSE infection may have led to retroperitoneal panniculitis and atypical STSS with delayed shock and flare of soft tissue inflammation.